Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2016 May 11;11(5):e0152621.
doi: 10.1371/journal.pone.0152621. eCollection 2016.

Outcomes of Adolescent and Adult Patients with Lung Metastatic Osteosarcoma and Comparison of Synchronous and Metachronous Lung Metastatic Groups

Ayse Gok Durnali  1 , Fatma Paksoy Turkoz  2 , Fisun Ardic Yukruk  3 , Saadet Tokluoglu  4 , Omer Kamil Yazici  1 , Ayse Demirci  1 , Oznur Bal  1 , Selay Gundogdu Buyukbas  1 , Onur Esbah  1 , Berna Oksuzoglu  1 , Necati Alkis  1
Affiliations
Comparative Study

Outcomes of Adolescent and Adult Patients with Lung Metastatic Osteosarcoma and Comparison of Synchronous and Metachronous Lung Metastatic Groups

Ayse Gok Durnali et al. PLoS One. .

Abstract

Osteosarcomas with lung metastases are rather heterogenous group. We aimed to evaluate the clinicopathological characteristics and outcomes of osteosarcoma patients with lung metastases and to compare the synchronous and metachronous lung metastatic groups. A total of 93 adolescent and adult patients with lung metastatic osteosarcoma, from March 1995 to July 2011, in a single center, were included. Sixty-five patients (69.9%) were male. The median age was 19 years (range, 14-74). Thirty-nine patients (41.9%) had synchronous lung metastases (Group A) and 54 patients (58.1%) had metachronous lung metastases (Group B). The 5-year and 10-year post-lung metastases overall survival (PLM-OS) was 17% and 15%, respectively. In multivariate analysis for PLM-OS, time to lung metastases (p = 0.010), number of metastatic pulmonary nodules (p = 0.020), presence of pulmonary metastasectomy (p = 0.007) and presence of chemotherapy for lung metastases (p< 0.001) were found to be independent prognostic factors. The median PLM-OS of Group A and Group B was 16 months and 9 months, respectively. In Group B, the median PLM-OS of the patients who developed lung metastases within 12 months was 6 months, whereas that of the patients who developed lung metastases later was 16 months. Time to lung metastases, number and laterality of metastatic pulmonary nodules, chemotherapy for lung metastatic disease and pulmonary metastasectomy were independent prognostic factors for patients with lung metastatic osteosarcoma. The best PLM-OS was in the subgroup of patients treated both surgery and chemotherapy. The prognosis of the patients who developed lung metastases within 12 months after diagnosis was worst.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. Post-lung metastases survival (PLM-OS) for the time to first lung metastses and for the treatment modalities.
Fig 2
Fig 2. Overall survival for the treatment modalities for lung metastases.
Fig 3
Fig 3. Post-lung metastases survival (PLM-OS) for the presence of pulmonary metastasectomy.
See this image and copyright information in PMC

References

    1. Ritter J, Bielack SS. Osteosarcoma. Ann Oncol 2010. October;21(Suppl 7):vii320–5. 10.1093/annonc/mdq276 - DOI - PubMed
    1. Kempf-Bielack B, Bielack SS., Jürgens H, Branscheid D, Berdel WE, Exner GU, et al. Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). J Clin Oncol 2005;23(3):559–568. - PubMed
    1. Aljubran AH, Griffin A, Pintilie M, Blackstein M. Osteosarcoma in adolescents and adults: survival analysis with and without lung metastases. Ann Oncol 2009;20(6):1136–1141. 10.1093/annonc/mdn731 - DOI - PubMed
    1. Kager L, Zoubek A, Pötschger U, Kastner U, Flege S, Kempf-Bielack B, et al. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol 2003;21(10):2011–2018. - PubMed
    1. Meyers PA, Heller G, Healey JH, Huvos A, Applewhite A, Sun M, et al. Osteogenic sarcoma with clinically detecetable metastasis at initial presentation. J Clin Oncol 1993; 11: 449–453. - PubMed

Publication types